GSK has announced it is investing over £270m to build a new vaccine manufacturing facility at its Wavre campus in Belgium. The new unit will handle freeze-dried vaccines, including Arexvy for RSV, as well as the company’s fast-growing shingles vaccine, Shingrix, and its malaria vaccine, Mosquirix. The plant will contain two wings: one for producing the UK company’s ‘non-live’ vaccines, and the other for making ‘live’ vaccines, which include Varilrix for chickenpox and Priorix for measles. Source: PMLive. 5/9/2023